Evidence map›Paper›PMID 29294238›Full record

ArticleNeurotoxicity research2018

Effects of the Positive Allosteric Modulator of Metabotropic Glutamate Receptor 5, VU-29, on Impairment of Novel Object Recognition Induced by Acute Ethanol and Ethanol Withdrawal in Rats.

Marta Marszalek-Grabska, Ewa Gibula-Bruzda, Anna Bodzon-Kulakowska, Piotr Suder, Kinga Gawel, Joanna Filarowska, Joanna Listos, Wojciech Danysz, Jolanta H Kotlinska

Open access · hybridAbstract read
In one paragraph

Article in Neurotoxicity research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Marta Marszalek-GrabskaDepartment of Pharmacology and Pharmacodynamics, Medical University, Chodzki 4A, 20-093, Lublin, Poland.
Ewa Gibula-BruzdaDepartment of Pharmacology and Pharmacodynamics, Medical University, Chodzki 4A, 20-093, Lublin, Poland.
Anna Bodzon-KulakowskaDepartment of Biochemistry and Neurobiology, AGH University of Science and Technology, Krakow, Poland.
Piotr SuderDepartment of Biochemistry and Neurobiology, AGH University of Science and Technology, Krakow, Poland.
Kinga GawelDepartment of Pharmacology and Pharmacodynamics, Medical University, Chodzki 4A, 20-093, Lublin, Poland.
Joanna FilarowskaDepartment of Pharmacology and Pharmacodynamics, Medical University, Chodzki 4A, 20-093, Lublin, Poland.
Joanna ListosDepartment of Pharmacology and Pharmacodynamics, Medical University, Chodzki 4A, 20-093, Lublin, Poland.
Wojciech DanyszMerz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
Jolanta H KotlinskaDepartment of Pharmacology and Pharmacodynamics, Medical University, Chodzki 4A, 20-093, Lublin, Poland. jolanta.kotlinska@umlub.pl.
Medical University of Lublin · PLAGH University of Krakow · PLMerLion Pharma (Germany) · DE

Funding

Statutory Funds of the Medical University of Lublin DS 22/16
6 · The paper itself

Abstract

Glutamate is essential for learning and memory processes, and acute and chronic exposures to ethanol (or protracted abstinence) alter glutamatergic transmission. In the current study, we investigated the effects of VU-29, positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor, on the acute ethanol- and ethanol withdrawal-induced impairment of novel object recognition (NOR) task in rats. The influence of VU-29 (30 mg/kg) on memory retrieval was measured (a) at 4-h delay after acute ethanol administration, as well as (b) after acute withdrawal (24 and 48 h) of repeated (2.0 g/kg, once daily for 7 days) ethanol administration. Additionally, the effects of VU-29 on expression of mGlu5 and mGlu2 receptor proteins in the hippocampus, prefrontal cortex, and striatum were determined 48 h after ethanol withdrawal. Our results indicated that VU-29, given before acute ethanol administration, prevented the ethanol-induced impairments in spatial memory retrieval. Furthermore, VU-29 given before the testing session on the first day of abstinence facilitated NOR performance in ethanol-withdrawn rats at 4- and 24-h delay after administration. Our ELISA results show that VU-29 normalized ethanol withdrawal induced increase in expression of mGlu5 receptor protein in the hippocampus, prefrontal cortex, and striatum, as well as expression of mGlu2 receptor protein in the hippocampus. Thus, results from our study indicate that positive modulation of mGlu5 receptor prevented and reversed ethanol-induced memory impairment. Moreover, mGlu5 (hippocampus, prefrontal cortex, and striatum) and mGlu2 (hippocampus) receptors play an important role in the ethanol-induced recognition memory impairment induced by ethanol withdrawal.

Indexed as

Substance Withdrawal SyndromeAllosteric RegulationAnimalsBenzamidesBrainCentral Nervous System DepressantsDisease Models, AnimalDose-Response Relationship, DrugEthanolHippocampusLocomotionMaleMaze LearningMemory DisordersPyrazolesRatsBenzamidesCentral Nervous System DepressantsEthanolN-(1,3-diphenyl-1H-pyrazolo-5-yl)-4-nitrobenzamidePyrazolesReceptor, Metabotropic Glutamate 5EthanolmGlu5 receptorNovel object recognitionVU-29

Identifiers

PMID29294238
PMCPMC5871646
OpenAlexW2781927229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.